Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - colchicine - oral tablet - 500microgram

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ulipristal acetate 5mg - tablet - 5 mg - active: ulipristal acetate 5mg excipient: croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose purified talc - ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

macleods pharma uk ltd - colchicine - oral tablet - 500microgram

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; indigo carmine aluminium lake; maize starch; propylene glycol; purified talc; quinoline yellow aluminium lake; sodium lauryl sulfate; titanium dioxide - treatment of schizophrenia and related psychoses.,short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,treatment of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe demetia of the alzheimer type). *(see dosage and administration: behavioural disturbances in dementia),risperidone is indicated for the treatment *(up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. *(see dosage and administration: behavioural disturbances in dementia),treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; hypromellose; maize starch; propylene glycol; purified talc; quinoline yellow aluminium lake; sodium lauryl sulfate; titanium dioxide - treatment of schizophrenia and related psychoses.,short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,treatment of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe demetia of the alzheimer type). *(see dosage and administration: behavioural disturbances in dementia),risperidone is indicated for the treatment *(up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. *(see dosage and administration: behavioural disturbances in dementia),treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; lactose monohydrate; magnesium stearate; hypromellose; maize starch; propylene glycol; purified talc; sodium lauryl sulfate; sunset yellow fcf aluminium lake; titanium dioxide - treatment of schizophrenia and related psychoses.,short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,treatment of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe demetia of the alzheimer type). *(see dosage and administration: behavioural disturbances in dementia),risperidone is indicated for the treatment *(up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. *(see dosage and administration: behavioural disturbances in dementia),treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica; magnesium stearate; hypromellose; maize starch; propylene glycol; purified talc; sodium lauryl sulfate - treatment of schizophrenia and related psychoses.,short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,treatment of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe demetia of the alzheimer type). *(see dosage and administration: behavioural disturbances in dementia),risperidone is indicated for the treatment *(up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. *(see dosage and administration: behavioural disturbances in dementia),treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; lactose monohydrate; hypromellose; iron oxide red; maize starch; propylene glycol; purified talc; sodium lauryl sulfate; titanium dioxide - treatment of schizophrenia and related psychoses.,short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,treatment of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe demetia of the alzheimer type). *(see dosage and administration: behavioural disturbances in dementia),risperidone is indicated for the treatment *(up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. *(see dosage and administration: behavioural disturbances in dementia),treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Amerika Serikat - Inggris - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. it may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. propranolol hydrochloride extended-release capsules are not indicated in the management of hypertensive emergencies. propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. the efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. propranolol hydrochloride extended-release capsules improve nyha functional class in symptomatic patients with hypertrophic subaortic stenosis. propranolol is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first-degree block; 3)

Israel - Inggris - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 100 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who are homozygous for the f508del mutation in the cftr gene limitations of use the efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation